Immunosuppressants - Morocco

Morocco

in Morocco, a country known for its rich history and vibrant culture, is also a significant player in the global Immunosuppressants market.
The projected revenue for this market in Morocco is estimated to reach US$20.87m by the year 2024.
This impressive figure is expected to grow at an annual growth rate of 15.54% (CAGR 2024-2029), resulting in a market volume of US$42.97m by 2029.
When comparing the revenue generated in the Immunosuppressants market globally, it becomes evident that United States takes the lead.
In 2024, [globalrevenue_currentlayer_yeartoday_maxcountrynameprep] is projected to generate a staggering revenue of US$35,470.00m, highlighting its dominance in this market.
Moroccan government's efforts to improve access to immunosuppressants have positively impacted the market's growth.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Immunosuppressants in Morocco has been on the rise in recent years.

Customer preferences: Moroccan customers have been increasingly opting for Immunosuppressants owing to the rise in the number of organ transplants and autoimmune diseases in the country. The Immunosuppressants market in Morocco has been dominated by branded drugs due to the lack of generic drug availability and the perception of better quality associated with branded drugs.

Trends in the market: The Immunosuppressants market in Morocco has been witnessing a shift towards biologic drugs owing to their higher efficacy and fewer side effects compared to conventional drugs. Additionally, the introduction of biosimilars in the market has been driving the growth of the Immunosuppressants market in Morocco. Moreover, the government's initiatives to increase healthcare coverage and the rise in healthcare expenditure have been contributing to the growth of the Immunosuppressants market in Morocco.

Local special circumstances: Morocco has a high prevalence of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus. Additionally, the country has a high demand for organ transplants, which has been driving the growth of the Immunosuppressants market in Morocco. However, the lack of awareness about the availability of Immunosuppressants and their benefits among the general population has been hindering the growth of the market.

Underlying macroeconomic factors: The rise in healthcare expenditure and the government's initiatives to increase healthcare coverage have been contributing to the growth of the Immunosuppressants market in Morocco. Additionally, the increase in the number of organ transplants and the prevalence of autoimmune diseases in the country have been driving the growth of the market. However, the lack of generic drug availability and the high cost of branded drugs have been hindering the growth of the Immunosuppressants market in Morocco.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.